GOSS - Gossamer Bio undergoes strategic restructuring; 25% of staff laid off
2023-05-10 15:14:24 ET
- Gossamer Bio ( NASDAQ: GOSS ) is undergoing a strategic restructuring that includes laying off more than 25% of its employees and focusing exclusively on seralutinib for pulmonary arterial hypertension.
- The company said it is on schedule to begin a phase 3 trial of seralutinib in the coming months.
- It added that is looking at strategic options for its portfolio of clinical and non-clinical candidates.
- Gossamer said that its cash, cash equivalents and marketable securities on hand are enough to fund operations for another year.
- Seeking Alpha's Quant Rating has viewed Gossamer ( GOSS ) as a strong sell since December 2022.
For further details see:
Gossamer Bio undergoes strategic restructuring; 25% of staff laid off